The downsizing, Hoge added, will help Moderna adjust to the endemic phase of the disease, which had led to falling demand for COVID vaccines as payers scale back orders for the shots.
Moderna predicted in August that U.S. demand for the vaccine would reach 50 to 100 million doses in the fall season.
Following the U.S. Food and Drug Administration's authorization on Monday, Moderna said it would start shipping COVID vaccine doses across the United States.
The effectiveness of Moderna's flu vaccine was demonstrated across all age groups, including older patients, and was found to be safe and tolerable, according to the company.
Moderna also said it had found that its shot was equal or superior to Sanofi's high-dose flu vaccine in a separate early head-to-head study.
Persons:
Stephen Hoge, Hoge, Moderna, we've, We've, COVID, Patrick Wingrove, Bhanvi, Will Dunham
Organizations:
Moderna, Sanofi, Wednesday, U.S . Centers for Disease Control, U.S . Food, Thomson
Locations:
Moderna, Massachusetts, United States, Britain, Canada, Japan, China, New York, Bengaluru